



Article

General Method of Synthesis of 5-(Het)arylarnino-1,2,3-triazoles via Buchwald–Hartwig Reaction of 5-Amino- or 5-Halo-1,2,3-triazoles

Pavel S. Gribanov ^{1,*}, Anna N. Philippova ¹, Maxim A. Topchiy ², Lidiya I. Minaeva ², Andrey F. Asachenko ² and Sergey N. Osipov ¹

¹ A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilova Str., 119991 Moscow, Russia; anyfil96@gmail.com (A.N.P.); osipov@ineos.ac.ru (S.N.O.)

² A.V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences, Leninskiy Prospect 29, 119991 Moscow, Russia; maxtopchiy@yandex.ru (M.A.T.); minaeva.lidiya@gmail.com (L.I.M.); aasachenko@gmail.com (A.F.A.)

* Correspondence: gribanovps@mail.ru; Tel.: +7-499-135-6212

Abstract: An efficient access to the novel 5-(het)arylarnino-1,2,3-triazole derivatives has been developed. The method is based on Buchwald–Hartwig cross-coupling reaction of 5-Amino or 5-Halo-1,2,3-triazoles with (het)aryl halides and amines, respectively. As result, it was found that palladium complex [(THP-Dipp)Pd(cinn)Cl] bearing expanded-ring *N*-heterocyclic carbene ligand is the most active catalyst for the process to afford the target molecules in high yields.

Keywords: cross-coupling; amination; triazoles; palladium; carbene ligands; heterocycles



Citation: Gribanov, P.S.; Philippova, A.N.; Topchiy, M.A.; Minaeva, L.I.; Asachenko, A.F.; Osipov, S.N. General Method of Synthesis of 5-(Het)arylarnino-1,2,3-triazoles via Buchwald–Hartwig Reaction of 5-Amino- or 5-Halo-1,2,3-triazoles. *Molecules* **2022**, *27*, 1999. <https://doi.org/10.3390/molecules27061999>

Academic Editor: Joseph Sloop

Received: 28 February 2022

Accepted: 18 March 2022

Published: 20 March 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Nitrogen containing heterocycles, in particular five-membered azole systems, are common structural elements of many natural and synthetic biological active compounds. They serve as universal scaffolds for creating new organic molecules with set properties especially for the needs of biomolecular and medicinal chemistry as well as for materials science [1–6]. In the last few decades fully substituted and variously functionalized 1,2,3-triazoles, whose structure fragment is not found in nature, became one of the most interesting and widely used class of compounds due to their unique physicochemical properties and synthetic accessibility [7,8]. These compounds possess remarkable thermal and metabolic stability, large dipole moment, and capability for H-bond formation making them effective peptide bond isosteres [9–11] that result in a variety of applications in diverse fields of chemistry [12–20]. Among fully substituted 1,2,3-triazoles special attention is focused on 5-amino-1,2,3-triazoles and their 5-arylarnino derivatives, which exhibit very promising biological properties such as antiviral, antifungal, antiproliferative and antimetastatic activities. They also serve as activators of potassium channel and chelating agents and have a potential for treating inflammatory kidney diseases (Figure 1) [21–26].

Since the pioneering Dimroth works published in the beginning of the 20th century [27,28], keteniminate-mediated 1,3-dipolar cycloaddition (DCR) of organic azides with nitriles bearing an active methylene group provide one of the most efficient and straightforward methods to access to the 5-amino-1,2,3-triazole synthesis up to date (Scheme 1) [29–32].

Unfortunately this approach is not applicable to 5-amino substituted 1,2,3-triazoles including 5-arylarnino derivatives. The scope of the existing methods for the synthesis of these compounds is limited to a few examples and has a number of disadvantages. Thus, previously described methods for the preparation of 5-arylarnino-1,2,3-triazoles include: (1) interaction between hard accessible carbodiimides and diazo compounds [21]; (2) three-component amine/enolizable ketone/azide reaction leading to low yields of the target products [33]; (3) high temperature thermolysis of the 5-triazenyl-1,2,3-triazoles to

give a large amount of 2H-1,2,3-triazole as a by-product [34]; (4) base-mediated hydrolysis of 1,2,3-triazolo[1,5-a]quinazolin-5(4H)-ones [35] as well as Rh-catalyzed azide-alkyne cycloaddition of internal ynamides to afford *N,N*-disubstituted amino-1,2,3-triazoles [26].





Figure 1. Potential application of 5-amino-1,2,3-triazoles *N*-substituted derivatives.



Scheme 1. 1,3-Dipolar cycloaddition reaction (DCR) between aryl azides and monosubstituted acetonitriles.

On the other hand, in the past 30 years, palladium-catalyzed cross-coupling reactions leading to the formation of new C–N bonds have become a widely used tool both in academia and in industry [36,37]. This Buchwald–Hartwig amination is the most popular cross-coupling reaction [38–40] (Figure 2) to access a wide range of *N*-mono- and *N,N*-disubstituted arylamines [41]. Despite impressive advances in the field, coupling of heteroaromatic amines with (het)aryl halides still remains problematic, often requiring long reaction times and time-consuming searches for optimal conditions and catalytic systems [3,42–45]. There are no examples of Buchwald–Hartwig cross-coupling of 5-halo- and 5-amino-1,2,3-triazoles with (het)aryl amines and halides, respectively, to afford *N*-aryl amino derivatives except a report on synthesis of related 4-amino-1,2,3-triazoles (with just 3 examples) [46].

Therefore, taking into account the growing popularity of 5-amino-1,2,3-triazole derivatives in medical chemistry, the development of new efficient and robust approaches to their synthesis remains of great interest.






Figure 2. Simplified catalytic cycle for Buchwald–Hartwig amination reaction.

We have recently developed effective methods for obtaining 5-amino- [47] and 5-halo-1,2,3-triazoles [48] via one pot azide-nitrile cycloaddition/Dimroth rearrangement (Scheme 2a) and Cu(I)-catalyzed [3+2] cycloaddition reaction of Cu(I)-acetylide and aryl azides with subsequent Cu-triazolide halogenation (Scheme 2b). Based on our experience in Pd-catalyzed cross-couplings of hetaryl halides [49–52] and halo-1,2,3-triazoles [53,54] we would like to provide details of an efficient route to *N*-arylamino-1,2,3-triazoles using the Buchwald–Hartwig reaction of 5-amino or 5-halo-1,2,3-triazoles (Scheme 2c).

Previous works



This work




Scheme 2. Synthetic approach to 5-amino-1,2,3-triazoles (a), 5-halo-1,2,3-triazoles (b) and *N*-arylamino-1,2,3-triazoles (c).

2. Results and Discussion


We commenced our investigation with the reaction between 1-benzyl-4-phenyl-1,2,3-triazole-5-amine and 1-bromo-4-methylbenzene to screen for optimal conditions for the cross-coupling (Table 1). A series of palladium complexes with expanded-ring NHC ligands (Figure 3) were initially tested as they proved to be competent catalysts for Buchwald–Hartwig amination of (het)aryl halides with primary aryl amines [50,51]. We found that the reaction performed in the presence of 1.0 mol% (THP-Dipp)Pd(cinn)Cl and 1.2 equiv. of sodium *tert*-butoxide in 1,4-dioxane at 120 °C for 24 h yielded the desired 5-(*p*-tolyl)amino-1,2,3-triazole **2a** in 53% yield (Table 1, entry 1). The reaction did not reveal the full conversion of the starting materials (TLC and ¹H NMR analysis). The prolonged reaction time did not result in a better yield of the product. The increase of the Pd-catalyst loading up to 2 mol% and the base up to 3.0 equiv. almost led to quantitative formation of **2a** (entry 3). Other NHC-Pd complexes with allyl and metallyl ligands exhibited slightly less activity under tested conditions (entries 4, 5). The traditional Pd(OAc)₂/phosphine-based catalytic systems [55] were also tested, exhibiting insufficient activity for the process (entries 6–9).

Table 1. Screening of catalytic systems in the BHA reaction ¹.



Entry	[Pd] (mol.%)	Base (Equiv.)	Yield, %
1	(THP-Dipp)Pd(cinn)Cl (1)	<i>t</i> -BuONa (1.2)	53
2	(THP-Dipp)Pd(cinn)Cl (2)	<i>t</i> -BuONa (1.2)	86
3	(THP-Dipp)Pd(cinn)Cl (2)	<i>t</i> -BuONa (3.0)	97
4	(THP-Dipp)PdAllylCl (2)	<i>t</i> -BuONa (1.2)	73
5	(THP-Dipp)PdMetallylCl (2)	<i>t</i> -BuONa (1.2)	39
6	Pd(OAc) ₂ (2 mol %)/RuPhos (4)	<i>t</i> -BuONa (1.2)	30
7	Pd(OAc) ₂ (2 mol %)/SPhos (4)	<i>t</i> -BuONa (1.2)	5
8	Pd(OAc) ₂ (2 mol %)/DavePhos (4)	<i>t</i> -BuONa (1.2)	12
9	Pd(OAc) ₂ (2 mol %)/XPhos (4)	<i>t</i> -BuONa (1.2)	6
10	(THP-Dipp)Pd(cinn)Cl (2)	Cs ₂ CO ₃ (1.2)	16

¹ Reaction conditions: 1-benzyl-4-phenyl-1*H*-1,2,3-triazole-5-amine **1a** (0.5 mmol); 1-bromo-4-methylbenzene (1 equiv.); [Pd], base; 1,4-dioxane (2.5 mL); 120 °C, 24 h.




(THP-Dipp)Pd(cinn)Cl (THP-Dipp)Pd(allyl)Cl (THP-Dipp)Pd(methallyl)Cl

Figure 3. Structures of (THP-Dipp) Pd complexes.

With these optimized conditions in hand, different 5-amino-1,2,3-triazoles were involved in the Buchwald–Hartwig cross-coupling reactions with a wide range of aromatic and heteroaromatic halides bearing various substituents in their structures. As a result, we found that in all studied cases the nature and location of the substituent in the (het)aryl core


of both triazole and halide substrates doesn't significantly influence the reaction leading to the formation of the corresponding 5-amino-1,2,3-triazoles derivatives **2a–p** including sterically hindered *ortho*-Me aryl derivatives **2b**, **2f**, **2j** in good and excellent yields. It is noteworthy that the reaction works perfectly for both (het)aryl bromides and chlorides (Scheme 3).



Scheme 3. Buchwald–Hartwig cross-coupling of 5-amino-1,2,3-triazoles^{1,1}. Conditions: 5-amino-1,2,3-triazole (0.5 mmol); (het)aryl-Hal (1 equiv.); (THP-Dipp)Pd(cinn)Cl (2 mol %); *t*-BuONa (3 equiv.); 1,4-dioxane (2.5 mL); 120 °C under argon 24 h;² 4,6-Dichloropyrimidine (0.25 mmol); 5-aminotriazole (2.0 equiv.); (THP-Dipp)Pd(cinn)Cl (4 mol %), *t*-BuONa (6 equiv.).

Then, we studied the reversed variant of the Buchwald–Hartwig cross-coupling reaction, namely the interaction of 5-halo-1,2,3-triazoles with aryl amines. Fortunately, we found that the conditions for aminotriazole–aryl halide coupling proved to also be suitable for the combination of halotriazole–aryl amine. Thus, corresponding derivatives of 5-arylamino-1,2,3-triazoles such as *N*-(*p*-tolylamino) (**2a**, **2q**) and *N*-(2,4-dimethylamino) (**2r**) triazoles were obtained in good to excellent yields. Arylamines with electron-withdrawing CF₃ group(s) in aromatic ring (**2s** and **2t**) can also be successfully used for this reaction.

Example **2u** demonstrates that the method is also applicable for the preparation of 4-(N-arylamino)-1,2,3-triazoles from the corresponding 4-halo-1,2,3-triazoles, while their synthesis was previously described via coupling of 4-amino-1,2,3-triazoles [46] (Scheme 4).



Scheme 4. Buchwald–Hartwig cross-coupling of 4- and 5-halo-1,2,3-triazoles^{1,1}. Reaction conditions: 4- or 5-halo-1,2,3-triazole (0.5 mmol); aryl-NH₂ (1 equiv.); (THP-Dipp)Pd(cinn)Cl (2 mol %); *t*-BuONa (3 equiv.); 1,4-dioxane (2.5 mL); 120 °C under argon, 24 h.

3. Materials and Methods

3.1. General Information

All the reactions were carried out under argon atmosphere, and the solvents were distilled from appropriate drying agents prior to use. All reagents were used as purchased from Sigma-Aldrich (Munich, Germany). In the study, 1,4-disubstituted-5-chloro- [48] and 5-amino-1,2,3-triazoles [47] and 1-benzyl-4-bromo-5-methyl-1*H*-1,2,3-triazole [56] were synthesized according to published procedures. (THP-Dipp)Pd(cinn)Cl [57], (THP-Dipp)Pd(allyl)Cl [58] and (THP-Dipp)Pd(metallyl)Cl were synthesized according to published procedure [57] from corresponding NHC-silver (I) complexes. Analytical data was in accordance with the literature data. Analytical TLC was performed with Merck silica gel 60 F 254 plates (Darmstadt, Germany); visualization was accomplished with UV light or iodine vapors. Chromatography was carried out using Merck silica gel (Kieselgel 60, 0.063–0.200 mm, Darmstadt, Germany) and petroleum ether/ethyl acetate as an eluent. The NMR spectra were obtained with Bruker AV-400, Karlsruhe, Germany (400 MHz ¹H, 101 MHz ¹³C, 376 MHz ¹⁹F) using TMS and CCl₃F as references for ¹H and ¹⁹F NMR spectra, respectively. Chemical shifts for ¹H and ¹³C were reported as δ values (ppm).

3.2. General Procedure for Preparation of *N*-arylamino-1,2,3-triazoles via BHA Reaction of 5-Amino or 4(5)-halo-1,2,3-triazoles


Under argon in a Schlenk tube with magnetic stirring bar, corresponding amino- or halo-1,2,3-triazole (0.5 mmol), (het)arylhalide or primary amine (1.0 equiv.) were dissolved in dry 1,4-dioxane (2.5 mL) at room temperature. The solution was degassed with three freeze-pump-thaw cycles. Then 6.6 mg (0.01 mmol, 2 mol%) of (THP-Dipp)Pd(cinn)Cl and sodium *tert*-butoxide (3.0 equiv.) were added to the reaction mixture, and the reaction mixture was stirred at 120 °C (oil bath temperature) for 18 h. After cooling to room temperature, the reaction mixture was poured into water and extracted with dichloromethane (3 × 10 mL). The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. Purification by chromatography (eluent—hexane: ethyl acetate 4:1) gave analytically pure corresponding *N*-arylamino-1,2,3-triazole as a white solid.

3.3. Preparation and Characterization of Novel Compounds

(THP-Dipp)Pd(methallyl)Cl


The title compound was synthesized according to literature procedure [58] from (6-Dipp)AgBr and (2-Methylallyl)palladium(II) chloride dimer as a white powder (88% yield). ¹H NMR (400 MHz, Acetone-*d*₆) δ 7.40–7.11 (m, 6H), 3.85–3.56 (m, 7H), 3.33–3.18 (m, 2H), 2.88 (s, 1H), 2.67–2.59 (m, 2H), 2.53–2.37 (m, 2H), 1.51–1.15 (m, 24H), 1.02 (s, 2H). ¹³C DEPTQ-135 NMR (Acetone, 101 MHz): δ 214.8, 146.6, 143.8, 130.0, 129.1, 128.2, 125.5, 70.3, 50.3, 49.2, 47.0, 47.0, 29.1, 27.1, 25.2, 24.9, 22.9, 22.1, 21.2, 21.0. HRMS (ESI): calcd for C₃₂H₄₇N₂Pd [(THP-Dipp)Pd(methallyl)]⁺: 563.2775, 564.2788, 565.2781, 566.2808, 567.2777; found: 563.2776, 564.2795, 565.2788, 566.2810, 567.2780.

1-benzyl-5-(*p*-tolylamino)-4-phenyl-1*H*-1,2,3-triazole (**2a**)



From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 1-bromo-4-methylbenzene (165 mg, 97% yield) or from 1-benzyl-5-chloro-4-phenyl-1*H*-1,2,3-triazole and *p*-toluidine (163 mg, 96% yield), following general procedure, **2a** was obtained as a white solid, m.p. 181–182 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.82 (d, *J* = 7.0 Hz, 2H), 7.34–7.26 (m, 6H), 7.22–7.17 (m, 2H), 7.00 (d, *J* = 8.4 Hz, 2H), 6.45 (d, *J* = 8.4 Hz, 2H), 5.36 (s, 2H), 5.05 (s, 1H), 2.27 (s, 3H). ¹³C{¹H} NMR (101 MHz, Chloroform-*d*) δ 141.2, 140.9, 134.8, 132.1, 130.3, 130.0, 129.0, 128.7, 128.4, 128.0, 127.9, 126.0, 114.3, 51.4, 20.6. IR (ν /cm⁻¹): 737.34 (VS), 812 (VS), 1006 (S), 1072 (S), 1177 (S), 1251 (S), 1288 (S), 1325 (S), 1359 (S), 1422 (S), 1441 (S), 1518 (S), 1586 (S), 1610 (S), 1810 (M), 1888 (M), 1955 (M), 2980 (W), 3025 (W), 3249 (M). HRMS (ESI): calcd for C₂₂H₂₁N₄ [M+H]⁺: 341.1761; found: 341.1769.


1-benzyl-5-(*o*-tolylamino)-4-phenyl-1*H*-1,2,3-triazole (**2b**)



From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 1-bromo-2-methylbenzene, following general procedure, **2b** (165 mg, 97% yield) was obtained as a white solid, m.p. 193–195 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.76 (d, *J* = 7.0 Hz, 2H), 7.33–7.25 (m, 6H), 7.18–7.12 (m, 3H), 6.98 (t, *J* = 7.5 Hz, 1H), 6.83 (t, *J* = 7.4 Hz, 1H), 6.25 (d, *J* = 8.1 Hz, 1H), 5.33 (s, 2H), 4.82 (s, 1H), 2.12 (s, 3H). ¹³C{¹H} NMR (101 MHz, Chloroform-*d*) δ 141.5, 141.0, 134.7, 131.9, 131.1, 130.4, 129.0, 128.8, 128.5, 128.1, 127.8, 127.6, 125.9, 123.3, 120.7, 112.7, 51.8,


17.5. IR (ν/cm^{-1}): 3271 (W), 1606 (S), 1586 (S), 1571 (S), 1514 (S), 1496 (S), 1448 (S), 1411 (S), 1362 (S), 1294 (S), 1251 (S), 1159 (S), 1110 (S), 1073 (S), 1006 (S), 769 (VS), 747 (VS), 734 (VS), 717 (VS). HRMS (ESI): calcd for $\text{C}_{22}\text{H}_{21}\text{N}_4 [\text{M}+\text{H}]^+$: 341.1761; found: 341.1764.

*1-benzyl-5-(phenylamino)-4-phenyl-1*H*-1,2,3-triazole (2c)*




From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and bromobenzene, following general procedure, **2c** (151 mg, 93% yield) was obtained as a white solid, m.p. 187–188 °C. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.80 (dd, *J* = 8.3, 1.4 Hz, 2H), 7.31–7.24 (m, 6H), 7.20–7.15 (m, 4H), 6.87 (t, *J* = 7.4 Hz, 1H), 6.52 (d, *J* = 7.6 Hz, 2H), 5.34 (s, 2H), 5.14 (s, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, Chloroform-*d*) δ 143.6, 141.1, 134.7, 131.6, 130.2, 129.9, 129.0, 128.8, 128.5, 128.1, 127.9, 126.0, 120.7, 114.3, 51.5. IR (ν/cm^{-1}): 3234 (M), 3180 (W), 2930 (W), 1602 (S), 1582 (S), 1568 (S), 1496 (S), 1445 (S), 1422 (S), 1364 (S), 1325 (S), 1256 (S), 1236 (S), 1176 (S), 1151 (S), 1077 (S), 770 (VS), 752 (VS). HRMS (ESI): calcd for $\text{C}_{21}\text{H}_{19}\text{N}_4 [\text{M}+\text{H}]^+$: 327.1604; found: 327.1608.

*1-benzyl-5-((4-benzonitrile)amino)-4-phenyl-1*H*-1,2,3-triazole (2d)*




From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 4-bromobenzonitrile, following general procedure, **2d** (172 mg, 98% yield) was obtained as a white solid, m.p. 179–180 °C. ^1H NMR (400 MHz, DMSO-*d*₆) δ 9.02 (s, 1H), 7.74 (d, *J* = 7.9 Hz, 2H), 7.48 (d, *J* = 8.5 Hz, 2H), 7.37 (t, *J* = 7.6 Hz, 2H), 7.31–7.24 (m, 4H), 7.19–7.15 (m, 2H), 6.52 (d, *J* = 8.6 Hz, 2H), 5.45 (s, 2H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, DMSO-*d*₆) δ 148.5, 139.2, 135.2, 133.8, 130.7, 130.0, 128.8, 128.6, 128.0, 127.9, 127.8, 125.2, 119.6, 113.8, 100.3, 50.2. IR (ν/cm^{-1}): 2962 (M), 2927 (W), 2223 (M), 1604 (S), 1590 (S), 1519 (S), 1456 (S), 1434 (S), 1426 (S), 1358 (S), 1323 (S), 1258 (S), 1173 (S), 1006 (S), 822 (VS), 773 (VS), 734 (VS), 716 (VS), 696 (VS). HRMS (ESI): calcd for $\text{C}_{22}\text{H}_{18}\text{N}_5 [\text{M}+\text{H}]^+$: 352.1557; found: 352.1556.

*1-tert-butyl-5-(*p*-tolylamino)-4-phenyl-1*H*-1,2,3-triazole (2e)*




From 1-*tert*-butyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 1-bromo-4-methylbenzene, following general procedure, **2e** (100 mg, 65% yield) was obtained as a white solid, m.p. 241–242 °C. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.80–7.74 (m, 2H), 7.28–7.20 (m, 3H), 6.97 (d, *J* = 6.5 Hz, 2H), 6.46 (d, *J* = 6.1 Hz, 2H), 5.25 (s, 1H), 2.22 (s, 3H), 1.68 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, Chloroform-*d*) δ 142.6, 142.3, 131.8, 130.6, 130.3, 129.3, 128.6, 127.8, 126.1, 114.2, 61.3, 29.8, 20.6. IR (ν/cm^{-1}): 3233 (M), 2975 (M), 1612 (S), 1593 (S), 1568 (S), 1516 (VS), 1449 (S), 1410 (S), 1371 (S), 1309 (VS), 1235 (S), 1195 (S), 991 (VS), 805 (VS), 762 (VS), 693 (VS). HRMS (ESI): calcd for $\text{C}_{19}\text{H}_{23}\text{N}_4 [\text{M}+\text{H}]^+$: 307.1917; found: 307.1921.

*1-benzyl-5-((4-fluoro-2-methylphenyl)amino)-4-phenyl-1*H*-1,2,3-triazole (2f)*




From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 1-bromo-4-fluoro-2-methylbenzene, following general procedure, **2f** (177 mg, >99% yield) was obtained as a white solid, m.p. 216–217 °C. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.74 (dd, *J* = 8.2, 1.2 Hz, 2H), 7.33 (t, *J* = 7.3 Hz, 2H), 7.31–7.27 (m, 4H), 7.16–7.12 (m, 2H), 6.90 (dd, *J* = 9.1, 2.7 Hz, 1H), 6.70–6.60 (m, 1H), 6.15 (dd, *J* = 8.7, 4.8 Hz, 1H), 5.35 (s, 2H), 4.74 (s, 1H), 2.12 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, Chloroform-*d*) δ 157.4 (d, *J* = 239.0 Hz), 140.7, 137.5 (d, *J* = 2.0 Hz), 134.6, 132.1, 130.4, 129.0, 128.9, 128.6, 128.2, 127.8, 125.9, 125.4 (d, *J* = 7.6 Hz), 117.8 (d, *J* = 22.8 Hz), 114.1 (d, *J* = 8.2 Hz), 113.6 (d, *J* = 22.3 Hz), 51.8, 17.6. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -123.92. IR (ν/cm^{-1}): 3241 (W), 1610 (S), 1588 (S), 1516 (S), 1498 (S), 1446 (S), 1411 (S), 1362 (S), 1268 (S), 1239 (S), 1199 (S), 1007 (S), 953 (S), 856 (VS), 800 (VS), 771 (VS), 737 (VS), 714 (VS), 697 (VS). HRMS (ESI): calcd for $\text{C}_{22}\text{H}_{20}\text{FN}_4$ [M+H] $^+$: 359.1667; found: 359.1670.

*1-tert-butyl-5-(phenylamino)-4-phenyl-1*H*-1,2,3-triazole (2g)*




From 1-tert-butyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and bromobenzene, following general procedure, **2g** (136 mg, 93% yield) was obtained as a white solid, m.p. 228–229 °C. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.76 (d, *J* = 7.3 Hz, 2H), 7.25–7.19 (m, 3H), 7.16 (t, *J* = 7.1 Hz, 2H), 6.81 (t, *J* = 7.3 Hz, 1H), 6.55 (d, *J* = 7.6 Hz, 2H), 5.58 (s, 1H), 1.68 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, Chloroform-*d*) δ 144.6, 142.5, 131.6, 130.2, 129.7, 128.6, 127.9, 126.2, 120.1, 114.1, 61.5, 29.8. IR (ν/cm^{-1}): 3346 (W), 3056 (W), 2980 (W), 2931 (W), 1604 (S), 1566 (S), 1498 (S), 1423 (S), 1370 (S), 1309 (S), 1233 (S), 1183 (S), 990 (VS), 768 (VS), 746 (VS), 717 (VS), 690 (VS). HRMS (ESI): calcd for $\text{C}_{18}\text{H}_{21}\text{N}_4$ [M+H] $^+$: 293.1761; found: 293.1766.


*1-benzyl-5-((pyridine-2-yl)amino)-4-phenyl-1*H*-1,2,3-triazole (2h)*




From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 2-bromopyridine, following general procedure, **2h** (127 mg, 77% yield) was obtained as a white solid, m.p. 173–174 °C. ^1H NMR (400 MHz, DMSO-*d*₆) δ 8.93 (s, 1H), 7.99–7.96 (m, 1H), 7.77 (d, *J* = 7.0 Hz, 2H), 7.57–7.52 (m, 1H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.32–7.25 (m, 4H), 7.19 (dd, *J* = 7.6, 1.8 Hz, 2H), 6.76–6.72 (m, 1H), 6.62 (d, *J* = 8.5 Hz, 1H), 5.40 (s, 2H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, Chloroform-*d*) δ 156.1, 148.0, 141.2, 138.6, 134.6, 130.4, 130.2, 128.8, 128.7, 128.4, 128.2, 128.1, 125.9, 115.9, 107.1, 51.6. IR (ν/cm^{-1}): 3140 (W), 3082 (W), 3062 (W), 2914 (M), 2856 (M), 1588 (S), 1522 (S), 1500 (S), 1436 (S), 1361 (S), 1319 (S), 1233 (S), 1213 (S), 1153 (VS), 1101 (S), 1074 (S), 996 (VS), 783 (VS), 772 (VS), 738 (VS). HRMS (ESI): calcd for $\text{C}_{20}\text{H}_{18}\text{N}_5$ [M+H] $^+$: 328.1557; found: 328.1561.

1-benzyl-5-((4-*tert*-butylphenyl)amino)-4-phenyl-1*H*-1,2,3-triazole (2i**)**


From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 1-bromo-4-*tert*-butylbenzene, following general procedure, **2i** (172 mg, 90% yield) was obtained as a white solid, m.p. 169–171 °C. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.81 (d, J = 7.0 Hz, 2H), 7.31–7.24 (m, 6H), 7.19–7.14 (m, 4H), 6.46 (d, J = 8.7 Hz, 2H), 5.33 (s, 2H), 5.07 (s, 1H), 1.27 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, Chloroform-*d*) δ 143.6, 141.0, 141.0, 134.8, 132.1, 130.4, 128.9, 128.8, 128.4, 128.0, 127.9, 126.6, 126.0, 114.1, 51.4, 34.2, 31.6. IR (ν/cm^{-1}): 3253 (M), 3054 (M), 3034 (M), 2956 (M), 2900 (M), 2857 (M), 1607 (S), 1587 (S), 1568 (S), 1515 (VS), 1400 (S), 1360 (S), 1252 (S), 1190 (S), 922 (S), 814 (S), 770 (VS), 737 (VS), 719 (VS), 695 (VS). HRMS (ESI): calcd for $\text{C}_{25}\text{H}_{27}\text{N}_4$ [M+H] $^+$: 383.2230; found: 383.2241.

1-benzyl-5-(mesitylamino)-4-phenyl-1*H*-1,2,3-triazole (2j**)**

From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 2-bromo-1,3,5-trimethylbenzene, following general procedure, **2j** (146 mg, 79% yield) was obtained as a white solid, m.p. 132–133 °C. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.71 (d, J = 7.3 Hz, 2H), 7.31–7.20 (m, 6H), 6.89 (dd, J = 7.2, 2.2 Hz, 2H), 6.72 (s, 2H), 5.15 (s, 2H), 4.93 (s, 1H), 2.23 (s, 3H), 1.75 (s, 6H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, Chloroform-*d*) δ 135.8, 135.1, 134.9, 134.9, 133.6, 131.2, 130.1, 129.8, 128.8, 128.4, 128.2, 127.2, 127.1, 126.2, 51.6, 20.7, 18.2. IR (ν/cm^{-1}): 3339 (M), 3060 (W), 3032 (M), 2913 (M), 2853 (W), 1606 (S), 1586 (S), 1571 (S), 1485 (S), 1445 (S), 1421 (S), 1361 (S), 1317 (S), 1250 (S), 1073 (S), 1029 (S), 994 (S), 840 (S), 769 (VS), 724 (VS), 694 (VS). HRMS (ESI): calcd for $\text{C}_{24}\text{H}_{25}\text{N}_4$ [M+H] $^+$: 369.2074; found: 369.2074.


1-*tert*-butyl-5-((pyridine-3-yl)amino)-4-phenyl-1*H*-1,2,3-triazole (2k**)**

From 1-*tert*-butyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 3-chloropyridine, following general procedure, **2k** (110 mg, 75% yield) was obtained as a white solid, m.p. 233–234 °C. ^1H NMR (400 MHz, DMSO-*d*₆) δ 8.27 (s, 1H), 7.94 (s, 1H), 7.90 (d, J = 4.7 Hz, 1H), 7.73 (d, J = 7.9 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.24 (t, J = 7.6 Hz, 1H), 7.08 (dd, J = 8.3, 4.6 Hz, 1H), 6.73 (d, J = 8.0 Hz, 1H), 1.65 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, DMSO-*d*₆) δ 141.6, 140.9, 139.9, 136.0, 131.1, 130.3, 128.6, 127.8, 125.4, 124.0, 119.5, 60.7, 29.1. IR (ν/cm^{-1}): 3252 (W), 3002 (W), 2974 (W), 1589 (S), 1580 (S), 1508 (S), 1477 (S), 1449 (S), 1370 (S), 1299 (S), 1239 (S), 990 (VS), 800 (VS), 772 (VS), 709 (VS). HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{20}\text{N}_5$ [M+H] $^+$: 294.1719; found: 294.1718.

1-phenethyl-5-((pyridine-3-yl)amino)-4-phenyl-1*H*-1,2,3-triazole (2l**)**


From 1-phenethyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 3-chloropyridine, following general procedure, **2l** (142 mg, 83% yield) was obtained as a white solid, m.p. 199–200 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.46 (s, 1H), 8.01–7.92 (m, 2H), 7.72 (d, *J* = 7.3 Hz, 2H), 7.35 (t, *J* = 7.4 Hz, 2H), 7.29–7.16 (m, 4H), 7.12 (d, *J* = 7.2 Hz, 2H), 7.07 (dd, *J* = 8.0, 4.6 Hz, 1H), 6.65 (dd, *J* = 8.5, 1.3 Hz, 1H), 4.44 (t, *J* = 7.3 Hz, 2H), 3.13 (t, *J* = 7.6 Hz, 2H). ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆) δ 140.6, 140.3, 138.3, 137.5, 136.4, 131.5, 130.3, 128.7, 128.6, 128.5, 127.7, 126.6, 125.2, 124.0, 119.7, 47.7, 35.0. IR (ν /cm^{−1}): 3203 (W), 3162 (W), 3083 (W), 3025 (W), 2969 (W), 1582 (S), 1569 (S), 1480 (S), 1455 (S), 1402 (S), 1361 (S), 1312 (S), 1278 (S), 1232 (S), 990 (S), 799 VS, 763 (VS), 743 (VS), 701 (VS). HRMS (ESI): calcd for C₂₁H₂₀N₅ [M+H]⁺: 342.1719; found: 342.1717.

*1-benzyl-5-((3,5-dimethylphenyl)amino)-4-phenyl-1*H*-1,2,3-triazole (2m)*




From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 1-bromo-3,5-dimethylbenzene, following general procedure, **2m** (149 mg, 84% yield) was obtained as a white solid, m.p. 154–155 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.82 (d, *J* = 7.0 Hz, 2H), 7.35–7.26 (m, 6H), 7.23–7.19 (m, 2H), 6.54 (s, 1H), 6.15 (s, 2H), 5.34 (s, 2H), 5.06 (s, 1H), 2.18 (s, 6H). ¹³C{¹H} NMR (101 MHz, Chloroform-*d*) δ 143.7, 141.1, 139.7, 134.8, 131.9, 130.4, 128.9, 128.8, 128.4, 128.1, 128.0, 126.0, 122.7, 112.2, 51.4, 21.5. IR (ν /cm^{−1}): 3266 (W), 2919 (W), 1601 (S), 1585 (S), 1495 (S), 1444 (S), 1353 (S), 1324 (S), 1233 (S), 1170 (S), 1004 (VS), 993 (VS), 837 (VS), 774 (VS), 739 (VS), 727 (VS), 691 (VS). HRMS (ESI): calcd for C₂₃H₂₃N₄ [M+H]⁺: 355.1917; found: 355.1920.

*1-benzyl-5-((pyrimidine-4-yl)amino)-4-phenyl-1*H*-1,2,3-triazole (2n)*



From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 4-chloropyrimidine, following general procedure, **2n** (161 mg, 98% yield) was obtained as a white solid, m.p. 156–157 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.40 (s, 1H), 8.10 (s, 1H), 7.93 (d, *J* = 5.6 Hz, 2H), 7.75 (d, *J* = 7.7 Hz, 2H), 7.38 (t, *J* = 7.6 Hz, 2H), 7.27 (q, *J* = 7.7, 6.7 Hz, 4H), 7.18 (d, *J* = 7.7 Hz, 2H), 5.44 (s, 2H). ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆) δ 152.5, 141.8, 139.4, 135.3, 135.0, 133.0, 130.5, 130.4, 128.7, 128.5, 127.8, 127.8, 127.8, 125.3, 50.5. IR (ν /cm^{−1}): 3189 (W), 3067 (W), 2953 (W), 1593 (S), 1497 (S), 1472 (S), 1446 (S), 1360 (S), 1318 (S), 1278 (S), 1231 (S), 1150 (S), 996 (S), 825 (VS), 767 (VS), 734 (VS), 694 (VS). HRMS (ESI) calcd for C₁₉H₁₇N₆ [M+H]⁺: 329.1515; found: 329.1514.


*1-benzyl-5-((pyridine-3-yl)amino)-4-phenyl-1*H*-1,2,3-triazole (2o)*



From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 3-chloropyridine (159 mg, 97% yield) or 3-bromopyridine (163 mg, >99% yield), following general procedure, **2o** was obtained as a white solid, m.p. 169–170 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.02–7.97


(m, 2H), 7.73 (dd, $J = 7.9, 1.6$ Hz, 2H), 7.27–7.22 (m, 3H), 7.21–7.17 (m, 3H), 7.15–7.11 (m, 2H), 6.92 (dd, $J = 8.3, 4.7$ Hz, 1H), 6.52 (ddd, $J = 8.3, 2.7, 1.2$ Hz, 1H), 6.30 (s, 1H), 5.36 (s, 2H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, Chloroform-*d*) δ 141.3, 141.3, 140.3, 136.9, 134.3, 130.6, 129.9, 129.0, 128.8, 128.6, 128.4, 127.9, 125.9, 124.1, 120.3, 51.6. IR (ν/cm^{-1}): 3221 (W), 3173 (M), 3090 (W), 3043 (M), 3027 (M), 2962 (M), 2904 (M), 2780 (M), 1608 (S), 1583 (S), 1570 (S), 1538 (S), 1480 (S), 1427 (S), 1409 (S), 1364 (S), 1321 (S), 1246 (S), 1234 (S), 1048 (S), 1006 (S), 994 (S). HRMS (ESI): calcd for $\text{C}_{20}\text{H}_{18}\text{N}_5$ [M+H] $^+$: 328.1557; found: 328.1561.

*N4,N6-bis(1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-yl)pyrimidine-4,6-diamine (2p)*




From 1-benzyl-4-phenyl-1*H*-1,2,3-triazol-5-amine and 4,6-dichloropyrimidine, following general procedure, **2p** (88 mg, 61% yield) was obtained as a white solid, m.p. 263–264 °C. ^1H NMR (400 MHz, DMSO-*d*₆) δ 9.28 (s, 2H), 7.98 (s, 1H), 7.73 (s, 4H), 7.40 (s, 4H), 7.37–7.29 (m, 3H), 7.28–7.10 (m, 10H), 5.38 (s, 4H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, DMSO-*d*₆) δ 161.3, 158.2, 139.4, 135.2, 130.2, 130.1, 128.7, 128.5, 127.9, 127.8, 125.3, 50.5. IR (ν/cm^{-1}): 3064 (M), 3032 (M), 2927 (M), 1601 (S), 1587 (S), 1496 (S), 1356 (S), 1288 (S), 1237 (S), 1188 (S), 1073 (S), 991 (S), 822 (VS), 769 (VS), 734 (VS), 720 (VS), 692 (VS). HRMS (ESI): calcd for $\text{C}_{34}\text{H}_{29}\text{N}_{10}$ [M+H] $^+$: 577.2571; found: 577.2574.

*1-phenethyl-5-(*p*-tolylamino)-4-phenyl-1*H*-1,2,3-triazole (2q)*



From 5-chloro-1-phenethyl-4-phenyl-1*H*-1,2,3-triazole and *p*-toluidine, following general procedure, **2q** (147 mg, 83% yield) was obtained as a white solid, m.p. 152–153 °C. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.74 (d, $J = 7.9$ Hz, 2H), 7.30–7.23 (m, 6H), 7.04–6.99 (m, 2H), 6.93 (d, $J = 8.0$ Hz, 2H), 6.29 (d, $J = 7.5$ Hz, 2H), 4.77 (s, 1H), 4.37 (t, $J = 8.3$ Hz, 2H), 3.14 (t, $J = 8.4$ Hz, 2H), 2.21 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, Chloroform-*d*) δ 140.8, 139.5, 137.6, 132.9, 130.2, 129.9, 129.1, 129.0, 128.7, 128.4, 127.3, 126.2, 125.9, 114.2, 49.2, 36.4, 20.6. IR (ν/cm^{-1}): 3205 (M), 3176 (M), 3085 (M), 3027 (M), 2950 (M), 2931 (M), 1878 (M), 1610 (S), 1585 (S), 1572 (S), 1520 (S), 1498 (S), 1451 (S), 1364 (S), 1258 (S), 1011 (S), 807 (VS), 762 (VS), 748 (VS), 699 (VS). HRMS (ESI): calcd for $\text{C}_{23}\text{H}_{23}\text{N}_4$ [M+H] $^+$: 355.1917; found: 355.1920.


*1-benzyl-5-((2,4-dimethylphenyl)amino)-4-phenyl-1*H*-1,2,3-triazole (2r)*



From 1-benzyl-5-chloro-4-phenyl-1*H*-1,2,3-triazole and 2,4-dimethylaniline, following general procedure, **2r** (169 mg, 95% yield) was obtained as a white solid, m.p. 194–195 °C. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.77 (d, $J = 7.5$ Hz, 2H), 7.33–7.24 (m, 6H), 7.16–7.11 (m, 2H), 6.99 (s, 1H), 6.78 (d, $J = 8.2$ Hz, 1H), 6.16 (d, $J = 8.1$ Hz, 1H), 5.31 (s, 2H), 4.84 (s, 1H), 2.25 (s, 3H), 2.11 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, Chloroform-*d*) δ 140.5, 139.0, 134.7, 132.5, 131.8, 130.2, 130.1, 129.0, 128.8, 128.5, 128.1, 127.9, 127.9, 126.0, 123.5, 113.0, 51.8, 20.6, 17.5. IR (ν/cm^{-1}): 3260 (W), 2962 (W), 2924 (W), 2857 (W), 1608 (S), 1587 (S), 1571 (S), 1517


(S), 1446 (S), 1360 (S), 1237 (S), 1156 (S), 804 (VS), 766 (VS), 736 (VS), 694 (VS). HRMS (ESI): calcd for $C_{23}H_{23}N_4 [M+H]^+$: 355.1917; found: 355.1918.

*1-benzyl-5-((3-(trifluoromethyl)phenyl)amino)-4-phenyl-1*H*-1,2,3-triazole (2s)*




From 1-benzyl-5-chloro-4-phenyl-1*H*-1,2,3-triazole and 3-(trifluoromethyl)aniline, following general procedure, **2s** (159 mg, 81% yield) was obtained as a white solid, m.p. 115–117 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.72 (dd, *J* = 6.4, 2.9 Hz, 2H), 7.23–7.11 (m, 9H), 7.05 (d, *J* = 7.7 Hz, 1H), 6.81 (s, 1H), 6.55 (d, *J* = 8.0 Hz, 1H), 6.41 (m, 1H), 5.32 (s, 2H). ¹³C{¹H} NMR (101 MHz, Chloroform-*d*) δ 144.3, 141.3, 134.2, 131.9 (q, *J* = 32.3 Hz), 131.1, 130.2, 129.8, 128.9, 128.8, 128.5, 128.3, 128.0, 125.9, 124.0 (q, *J* = 272.8 Hz), 116.9, 110.9 (q, *J* = 3.6 Hz), 51.5. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -62.8. IR (ν/cm^{-1}): 3195 (M), 3038 (M), 2927 (M), 1619 (S), 1586 (S), 1571 (S), 1495 (S), 1486 (S), 1444 (S), 1425 (S), 1336 (VS), 1231 (S), 1163 (VS), 1118 (VS), 1099 (S), 1067 (VS), 1006 (S), 996 (S), 916 (S), 871 (S), 791 (S), 769 (VS), 736 (VS), 692 (VS). HRMS (ESI): calcd for $C_{22}H_{18}F_3N_4 [M+H]^+$: 395.1478; found: 395.1482.

*1-benzyl-5-((3,5-bis(trifluoromethyl)phenyl)amino)-4-phenyl-1*H*-1,2,3-triazole (2t)*



From 1-benzyl-5-chloro-4-phenyl-1*H*-1,2,3-triazole and 3,5-bis(trifluoromethyl) aniline, following general procedure, **2t** (136 mg, 59% yield) was obtained as a white solid, m.p. 110–111 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.70 (dd, *J* = 7.7, 1.9 Hz, 2H), 7.35–7.26 (m, 4H), 7.24–7.22 (m, 3H), 7.16–7.11 (m, 2H), 6.75 (s, 2H), 5.52 (s, 1H), 5.42 (s, 2H). ¹³C{¹H} NMR (101 MHz, Chloroform-*d*) δ 144.8, 141.9, 133.8, 133.0 (q, *J* = 33.5 Hz), 129.8, 129.5, 129.2, 129.0, 128.8, 128.7, 127.9, 126.0, 125.8, 123.1 (q, *J* = 272.6 Hz), 113.8 (p, *J* = 3.8 Hz), 113.7, 113.6, 52.0. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -63.19. IR (ν/cm^{-1}): 3457 (W), 3204 (W), 3074 (W), 2930 (W), 1616 (S), 1590 (S), 1498 (S), 1471 (S), 1387 (S), 1276 (S), 1182 (S), 1130 (VS), 953 (VS), 873 (VS), 766 (VS), 700 (VS). HRMS (nESI): calcd for $C_{23}H_{17}F_6N_4 [M+H]^+$: 463.1357; found: 463.1348.

*1-benzyl-4-(*p*-tolylamino)-5-methyl-1*H*-1,2,3-triazole (2u)*



From 1-benzyl-4-bromo-5-methyl-1*H*-1,2,3-triazole and *p*-toluidine, following general procedure, **2u** (97 mg, 69% yield) was obtained as a white solid, m.p. 133–134 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.38–7.32 (m, 3H), 7.19 (d, *J* = 6.7 Hz, 2H), 6.98 (d, *J* = 8.3 Hz, 2H), 6.63 (d, *J* = 8.1 Hz, 2H), 5.61 (s, 1H), 5.48 (s, 2H), 2.24 (s, 3H), 2.02 (s, 3H). ¹³C{¹H} NMR (101 MHz, Chloroform-*d*) δ 144.7, 142.4, 134.6, 129.8, 129.2, 129.1, 128.5, 127.3, 125.1, 114.8, 52.9, 29.8, 20.6. IR (ν/cm^{-1}): 3246 (M), 3109 (W), 3034 (M), 2924 (M), 2855 (M), 1884 (M), 1602 (S), 1511 (S), 1455 (S), 1435 (S), 1390 (S), 1345 (S), 1234 (S), 1121 (S), 815 (VS), 725 (VS), 696 (VS). HRMS (ESI): calcd for $C_{17}H_{18}N_5 [M+H]^+$: 279.1604; found: 279.1606.

4. Conclusions

In conclusion, we have developed an efficient and robust method for the preparation of a series of new 5-(het)arylamino-1,2,3-triazole derivatives via Buchwald–Hartwig cross-coupling reaction of 5-amino or 5-halo-1,2,3-triazoles with (het)aryl halides and amines respectively. As a result of the careful screening for optimal conditions, a catalytic system based on the palladium complex [(THP-Dipp)Pd(cinn)Cl] with expanded-ring NHC ligand has been revealed as the most active for the process. The reaction functions perfectly in 1,4-dioxane medium at 120 °C in the presence of an excess of *t*-BuONa to afford a variety of 5-(het)arylamino-1,2,3-triazoles with good to excellent yields. The compounds obtained have major potential to be used in biomolecular chemistry and material science.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/molecules27061999/s1>, copies of ^1H and ^{13}C NMR spectra for all novel compounds.

Author Contributions: Conceptualization, P.S.G., A.F.A., S.N.O.; methodology, P.S.G.; investigation, P.S.G. (synthesis, NMR spectra registering and characterization), A.N.P. (synthesis), A.F.A., L.I.M., M.A.T. (synthesis of (THP-Dipp)Pd(allyl)Cl and (THP-Dipp)PdMetallylCl complexes); writing—original draft preparation, P.S.G., S.N.O.; writing—review and editing, P.S.G., S.N.O.; supervision, P.S.G.; project administration, P.S.G.; funding acquisition, P.S.G. All authors have read and agreed to the published version of the manuscript.

Funding: This work was financially supported by the Russian Science Foundation (grant RSF No. 20-73-00291).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the article and Supplementary Materials.

Acknowledgments: NMR studies and spectral characterization were performed with financial support from the Ministry of Science and Higher Education of the Russian Federation using the equipment of the Center for Molecular Composition Studies of INEOS RAS. Part of this work (synthesis of (THP-Dipp)Pd(allyl)Cl and (THP-Dipp)Pd(methallyl)Cl complexes) was carried out as a part of the State Program of A. V. Topchiev Institute of Petrochemical Synthesis of the Russian Academy of Sciences (TIPS RAS).

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of all of the compounds are available from the authors.

References

- Thansandote, P.; Lautens, M. Construction of nitrogen-containing heterocycles by C-H bond functionalization. *Chem. Eur. J.* **2009**, *15*, 5874–5883. [[CrossRef](#)] [[PubMed](#)]
- Chen, D.; Su, S.-J.; Cao, Y. Nitrogen heterocycle-containing materials for highly efficient phosphorescent OLEDs with low operating voltage. *J. Mater. Chem. C* **2014**, *2*, 9565–9578. [[CrossRef](#)]
- Huang, W.; Buchwald, S.L. Palladium-Catalyzed N-Arylation of Iminodibenzyls and Iminostilbenes with Aryl- and Heteroaryl Halides. *Chem. Eur. J.* **2016**, *22*, 14186–14189. [[CrossRef](#)] [[PubMed](#)]
- Bikker, J.A.; Brooijmans, N.; Wissner, A.; Mansour, T.S. Kinase domain mutations in cancer: Implications for small molecule drug design strategies. *J. Med. Chem.* **2009**, *52*, 1493–1509. [[CrossRef](#)] [[PubMed](#)]
- Quintas-Cardama, A.; Kantarjian, H.; Cortes, J. Flying under the radar: The new wave of BCR-ABL inhibitors. *Nat. Rev. Drug. Discov.* **2007**, *6*, 834–848. [[CrossRef](#)]
- Topchii, M.A.; Zharkova, D.A.; Asachenko, A.F.; Muzalevskiy, V.M.; Chertkov, V.A.; Nenajdenko, V.G.; Nechaev, M.S. Mild and Regioselective Synthesis of 3-CF₃-Pyrazoles by the AgOTf-Catalysed Reaction of CF₃-Ynones with Hydrazines. *Eur. J. Org. Chem.* **2018**, *2018*, 3750–3755. [[CrossRef](#)]
- Sharma, P.; Kumar, A.V.; Upadhyay, S.; Singh, J.; Sahu, V. A novel approach to the synthesis of 1,2,3-triazoles and their SAR studies. *Med. Chem. Res.* **2009**, *19*, 589–602. [[CrossRef](#)]
- Gomes, A.; Martins, P.; Rocha, D.R.; Neves, M.; Ferreira, V.F.; Silva, A.; Cavaleiro, J.; da Silva, F. Consecutive Tandem Cycloaddition between Nitriles and Azides; Synthesis of 5-Amino-1*H*-[1,2,3]-triazoles. *Synlett* **2013**, *24*, 41–44. [[CrossRef](#)]
- Dheer, D.; Singh, V.; Shankar, R. Medicinal attributes of 1,2,3-triazoles: Current developments. *Bioorg. Chem.* **2017**, *71*, 30–54. [[CrossRef](#)]

10. Bonandi, E.; Christodoulou, M.S.; Fumagalli, G.; Perdicchia, D.; Rastelli, G.; Passarella, D. The 1,2,3-triazole ring as a bioisostere in medicinal chemistry. *Drug Discov. Today* **2017**, *22*, 1572–1581. [[CrossRef](#)]
11. Lauria, A.; Delisi, R.; Mingoia, F.; Terenzi, A.; Martorana, A.; Barone, G.; Almerico, A.M. 1,2,3-Triazole in Heterocyclic Compounds, Endowed with Biological Activity, through 1,3-Dipolar Cycloadditions. *Eur. J. Org. Chem.* **2014**, *2014*, 3289–3306. [[CrossRef](#)]
12. Johansson, J.R.; Beke-Somfai, T.; Said Stalsmeden, A.; Kann, N. Ruthenium-Catalyzed Azide Alkyne Cycloaddition Reaction: Scope, Mechanism, and Applications. *Chem. Rev.* **2016**, *116*, 14726–14768. [[CrossRef](#)] [[PubMed](#)]
13. Hein, J.E.; Fokin, V.V. Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: New reactivity of copper(I) acetylides. *Chem. Soc. Rev.* **2010**, *39*, 1302–1315. [[CrossRef](#)] [[PubMed](#)]
14. Emileh, A.; Duffy, C.; Holmes, A.P.; Rosemary Bastian, A.; Aneja, R.; Tuzer, F.; Rajagopal, S.; Li, H.; Abrams, C.F.; Chaiken, I.M. Covalent conjugation of a peptide triazole to HIV-1 gp120 enables intramolecular binding site occupancy. *Biochemistry* **2014**, *53*, 3403–3414. [[CrossRef](#)]
15. Kuntala, N.; Telu, J.R.; Banothu, V.; Nallapati, S.B.; Anireddy, J.S.; Pal, S. Novel benzoxepine-1,2,3-triazole hybrids: Synthesis and pharmacological evaluation as potential antibacterial and anticancer agents. *Med. Chem. Commun.* **2015**, *6*, 1612–1619. [[CrossRef](#)]
16. Duan, H.; Sengupta, S.; Petersen, J.L.; Akhmedov, N.G.; Shi, X. Triazole-Au(I) complexes: A new class of catalysts with improved thermal stability and reactivity for intermolecular alkyne hydroamination. *J. Am. Chem. Soc.* **2009**, *131*, 12100–12102. [[CrossRef](#)]
17. Nandivada, H.; Jiang, X.; Lahann, J. Click Chemistry: Versatility and Control in the Hands of Materials Scientists. *Adv. Mater.* **2007**, *19*, 2197–2208. [[CrossRef](#)]
18. Ashok, D.; Chiranjeevi, P.; Kumar, A.V.; Sarasiya, M.; Krishna, V.S.; Sriram, D.; Balasubramanian, S. 1,2,3-Triazole-fused spirochromenes as potential anti-tubercular agents: Synthesis and biological evaluation. *RSC Adv.* **2018**, *8*, 16997–17007. [[CrossRef](#)]
19. Azagarsamy, M.A.; Anseth, K.S. Bioorthogonal Click Chemistry: An Indispensable Tool to Create Multifaceted Cell Culture Scaffolds. *ACS Macro Lett.* **2013**, *2*, 5–9. [[CrossRef](#)]
20. Johnson, J.A.; Finn, M.G.; Koberstein, J.T.; Turro, N.J. Construction of Linear Polymers, Dendrimers, Networks, and Other Polymeric Architectures by Copper-Catalyzed Azide-Alkyne Cycloaddition “Click” Chemistry. *Macromol. Rapid Commun.* **2008**, *29*, 1052–1072. [[CrossRef](#)]
21. Wang, S.; Zhang, Y.; Liu, G.; Xu, H.; Song, L.; Chen, J.; Li, J.; Zhang, Z. Transition-metal-free synthesis of 5-amino-1,2,3-triazoles via nucleophilic addition/cyclization of carbodiimides with diazo compounds. *Org. Chem. Front.* **2021**, *8*, 599–604. [[CrossRef](#)]
22. Ferrini, S.; Chandanshive, J.Z.; Lena, S.; Comes Franchini, M.; Giannini, G.; Tafi, A.; Taddei, M. Ruthenium-catalyzed synthesis of 5-amino-1,2,3-triazole-4-carboxylates for triazole-based scaffolds: Beyond the dimroth rearrangement. *J. Org. Chem.* **2015**, *80*, 2562–2572. [[CrossRef](#)] [[PubMed](#)]
23. Dorokhov, V.A.; Komkov, A.V. Addition of acetylacetone and ethyl acetoacetate to carbodiimides promoted by nickel acetylacetone. *Russ. Chem. Bull.* **2004**, *53*, 676–680. [[CrossRef](#)]
24. Zhao, X.; Lu, B.W.; Lu, J.R.; Xin, C.W.; Li, J.F.; Liu, Y. Design, synthesis and antimicrobial activities of 1,2,3-triazole derivatives. *Chin. Chem. Lett.* **2012**, *23*, 933–935. [[CrossRef](#)]
25. Lauria, A.; Abbate, I.; Patella, C.; Martorana, A.; Dattolo, G.; Almerico, A.M. New annelated thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidines, with potent anticancer activity, designed through VLAK protocol. *Eur. J. Med. Chem.* **2013**, *62*, 416–424. [[CrossRef](#)]
26. Liao, Y.; Lu, Q.; Chen, G.; Yu, Y.; Li, C.; Huang, X. Rhodium-Catalyzed Azide–Alkyne Cycloaddition of Internal Ynamides: Regioselective Assembly of 5-Amino-Triazoles under Mild Conditions. *ACS Catal.* **2017**, *7*, 7529–7534. [[CrossRef](#)]
27. Dimroth, O. Ueber eine Synthese von Derivaten des 1,2,3-Triazols. *Eur. J. Inorg. Chem.* **1902**, *35*, 1029–1038.
28. Dimroth, O. Ueber intramolekulare Umlagerungen. Umlagerungen in der Reihe des 1,2,3-Triazols. *Justus Liebigs Ann. Chem.* **1909**, *364*, 183–226. [[CrossRef](#)]
29. Krishna, P.M.; Ramachary, D.B.; Peesapati, S. Azide–acetonitrile “click” reaction triggered by Cs₂CO₃: The atom-economic, high-yielding synthesis of 5-amino-1,2,3-triazoles. *RSC Adv.* **2015**, *5*, 62062–62066. [[CrossRef](#)]
30. Lieber, E.; Chao, T.S.; Ramachandra Rao, C.N. Synthesis and Isomerization of Substituted 5-Amino-1,2,3-triazoles1. *J. Org. Chem.* **2002**, *22*, 654–662. [[CrossRef](#)]
31. Cottrell, I.F.; Hands, D.; Houghton, P.G.; Humphrey, G.R.; Wright, S.H.B. An improved procedure for the preparation of 1-benzyl-1H-1,2,3-triazoles from benzyl azides. *J. Heterocycl. Chem.* **1991**, *28*, 301–304. [[CrossRef](#)]
32. Pokhodlyo, N.T.; Matiychuk, V.S.; Obushak, N.B. Synthesis of 1H-1,2,3-triazole derivatives by the cyclization of aryl azides with 2-benzothiazolylacetone, 1,3-benzo-thiazol-2-ylacetonitrile, and (4-aryl-1,3-thiazol-2-yl)acetonitriles. *Chem. Heterocycl. Compd.* **2009**, *45*, 483–488. [[CrossRef](#)]
33. Opsomer, T.; Thomas, J.; Dehaen, W. Chemoslectivity in the Synthesis of 1,2,3-Triazoles from Enolizable Ketones, Primary Alkylamines, and 4-Nitrophenyl Azide. *Synthesis* **2017**, *49*, 4191–4198.
34. Navarro, Y.; Garcia Lopez, J.; Iglesias, M.J.; Lopez Ortiz, F. Chelation-Assisted Interrupted Copper(I)-Catalyzed Azide–Alkyne–Azide Domino Reactions: Synthesis of Fully Substituted 5-Triazeny1-1,2,3-triazoles. *Org. Lett.* **2021**, *23*, 334–339. [[CrossRef](#)] [[PubMed](#)]
35. Du, W.; Huang, H.; Xiao, T.; Jiang, Y. Metal-Free, Visible-Light Promoted Intramolecular Azole C–H Bond Amination Using Catalytic Amount of I₂: A Route to 1,2,3-Triazolo[1,5-a]quinazolin-5(4H)-ones. *Adv. Synth. Catal.* **2020**, *362*, 5124–5129. [[CrossRef](#)]
36. Roughley, S.D.; Jordan, A.M. The medicinal chemist’s toolbox: An analysis of reactions used in the pursuit of drug candidates. *J. Med. Chem.* **2011**, *54*, 3451–3479. [[CrossRef](#)] [[PubMed](#)]

37. Flick, A.C.; Ding, H.X.; Leverett, C.A.; Kyne, R.E., Jr.; Liu, K.K.; Fink, S.J.; O'Donnell, C.J. Synthetic Approaches to the New Drugs Approved During 2015. *J. Med. Chem.* **2017**, *60*, 6480–6515. [[CrossRef](#)] [[PubMed](#)]
38. Corbet, J.P.; Mignani, G. Selected patented cross-coupling reaction technologies. *Chem. Rev.* **2006**, *106*, 2651–2710. [[CrossRef](#)]
39. Heravi, M.M.; Kheirkordi, Z.; Zadsirjan, V.; Heydari, M.; Malmir, M. Buchwald-Hartwig reaction: An overview. *J. Organomet. Chem.* **2018**, *861*, 17–104. [[CrossRef](#)]
40. Wambua, V.; Hirschi, J.S.; Vetticatt, M.J. Rapid Evaluation of the Mechanism of Buchwald-Hartwig Amination and Aldol Reactions Using Intramolecular (13)C Kinetic Isotope Effects. *ACS Catal.* **2021**, *11*, 60–67. [[CrossRef](#)]
41. Liu, Y.-F.; Wang, C.-L.; Bai, Y.-J.; Han, N.; Jiao, J.-P.; Qi, X.-L. A Facile Total Synthesis of Imatinib Base and Its Analogues. *Org. Process Res. Dev.* **2008**, *12*, 490–495. [[CrossRef](#)]
42. Tundel, R.E.; Anderson, K.W.; Buchwald, S.L. Expedited palladium-catalyzed amination of aryl nonaflates through the use of microwave-irradiation and soluble organic amine bases. *J. Org. Chem.* **2006**, *71*, 430–433. [[CrossRef](#)] [[PubMed](#)]
43. Kumar, R.; Ramachandran, U.; Khanna, S.; Bharatam, P.V.; Raichur, S.; Chakrabarti, R. Synthesis, in vitro and in silico evaluation of l-tyrosine containing PPARalpha/gamma dual agonists. *Bioorg. Med. Chem.* **2007**, *15*, 1547–1555. [[CrossRef](#)]
44. Reddy, M.; Anusha, G.; Reddy, P. Sterically enriched bulky 1,3-bis(N,N'-aralkyl)benzimidazolium based Pd-PEPPI complexes for Buchwald-Hartwig amination reactions. *New J. Chem.* **2020**, *44*, 11694–11703. [[CrossRef](#)]
45. Deng, Q.; Zhang, Y.; Zhu, H.; Tu, T. Robust Acenaphthoimidazolylidene Palladacycles: Highly Efficient Catalysts for the Amination of N-Heteroaryl Chlorides. *Chem. Asian J.* **2017**, *12*, 2364–2368. [[CrossRef](#)] [[PubMed](#)]
46. Moss, T.; Addie, M.; Nowak, T.; Waring, M. Room-Temperature Palladium-Catalyzed Coupling of Heteroaryl Amines with Aryl or Heteroaryl Bromides. *Synlett* **2012**, *2012*, 285–289. [[CrossRef](#)]
47. Gribanov, P.S.; Atoian, E.M.; Philippova, A.N.; Topchiy, M.A.; Asachenko, A.F.; Osipov, S.N. One-Pot Synthesis of 5-Amino-1,2,3-triazole Derivatives via Dipolar Azide–Nitrile Cycloaddition and Dimroth Rearrangement under Solvent-Free Conditions. *Eur. J. Org. Chem.* **2021**, *2021*, 1378–1384. [[CrossRef](#)]
48. Gribanov, P.S.; Topchiy, M.A.; Karsakova, I.V.; Chesnokov, G.A.; Smirnov, A.Y.; Minaeva, L.I.; Asachenko, A.F.; Nechaev, M.S. General Method for the Synthesis of 1,4-Disubstituted 5-Halo-1,2,3-triazoles. *Eur. J. Org. Chem.* **2017**, *2017*, 5225–5230. [[CrossRef](#)]
49. Topchiy, M.A.; Asachenko, A.F.; Nechaev, M.S. Solvent-Free Buchwald-Hartwig Reaction of Aryl and Heteroaryl Halides with Secondary Amines. *Eur. J. Org. Chem.* **2014**, *2014*, 3319–3322. [[CrossRef](#)]
50. Topchiy, M.A.; Dzhevakov, P.B.; Rubina, M.S.; Morozov, O.S.; Asachenko, A.F.; Nechaev, M.S. Solvent-Free Buchwald-Hartwig (Hetero)arylation of Anilines, Diarylamines, and Dialkylamines Mediated by Expanded-Ring N-Heterocyclic Carbene Palladium Complexes. *Eur. J. Org. Chem.* **2016**, *2016*, 1908–1914. [[CrossRef](#)]
51. Chesnokov, G.A.; Gribanov, P.S.; Topchiy, M.A.; Minaeva, L.I.; Asachenko, A.F.; Nechaev, M.S.; Bermesheva, E.V.; Bermeshev, M.V. Solvent-free Buchwald-Hartwig amination with low palladium loadings. *Mendeleev Commun.* **2017**, *27*, 618–620. [[CrossRef](#)]
52. Ageshina, A.A.; Sterligov, G.K.; Rzhevskiy, S.A.; Topchiy, M.A.; Chesnokov, G.A.; Gribanov, P.S.; Melnikova, E.K.; Nechaev, M.S.; Asachenko, A.F.; Bermeshev, M.V. Mixed er-NHC/phosphine Pd(ii) complexes and their catalytic activity in the Buchwald-Hartwig reaction under solvent-free conditions. *Dalton. Trans.* **2019**, *48*, 3447–3452. [[CrossRef](#)] [[PubMed](#)]
53. Gribanov, P.S.; Chesnokov, G.A.; Dzhevakov, P.B.; Kirilenko, N.Y.; Rzhevskiy, S.A.; Ageshina, A.A.; Topchiy, M.A.; Bermeshev, M.V.; Asachenko, A.F.; Nechaev, M.S. Solvent-free Suzuki and Stille cross-coupling reactions of 4- and 5-halo-1,2,3-triazoles. *Mendeleev Commun.* **2019**, *29*, 147–149. [[CrossRef](#)]
54. Gribanov, P.S.; Chesnokov, G.A.; Topchiy, M.A.; Asachenko, A.F.; Nechaev, M.S. A general method of Suzuki-Miyaura cross-coupling of 4- and 5-halo-1,2,3-triazoles in water. *Org. Biomol. Chem.* **2017**, *15*, 9575–9578. [[CrossRef](#)] [[PubMed](#)]
55. Charles, M.D.; Schultz, P.; Buchwald, S.L. Efficient pd-catalyzed amination of heteroaryl halides. *Org. Lett.* **2005**, *7*, 3965–3968. [[CrossRef](#)] [[PubMed](#)]
56. Afanas'ev, O.I.; Tsypolenkova, O.A.; Seliverstov, M.Y.; Sosonyuk, S.E.; Proskurnina, M.V.; Zefirov, N.S. Homocoupling of bromotriazole derivatives on metal complex catalysts. *Russ. Chem. Bull.* **2016**, *64*, 1470–1472. [[CrossRef](#)]
57. Kolychev, E.L.; Asachenko, A.F.; Dzhevakov, P.B.; Bush, A.A.; Shuntikov, V.V.; Khrustalev, V.N.; Nechaev, M.S. Expanded ring diaminocarbene palladium complexes: Synthesis, structure, and Suzuki-Miyaura cross-coupling of heteroaryl chlorides in water. *Dalton. Trans.* **2013**, *42*, 6859–6866. [[CrossRef](#)]
58. Farmer, J.L.; Pompeo, M.; Lough, A.J.; Organ, M.G. [(IPent)PdCl₂(morpholine)]: A readily activated precatalyst for room-temperature, additive-free carbon-sulfur coupling. *Chem. Eur. J.* **2014**, *20*, 15790–15798. [[CrossRef](#)]